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http:WHAT THIS ARTICLE ADDS
Successful application of the Cardiatis multilayer ﬂow modulator (CMFM) in the treatment of visceral, renal,
peripheral, and aorta aneurysms is described but limited to a small series. This single-center prospective registry
assesses the efﬁcacy of the CMFM in the treatment of complex aorta aneurysms. The device preserves ﬂow into
covered aortic branches. Completed thrombosis and aneurysm shrinkage occurs gradually and partially. This
means that patients are not instantly protected from rupture after stent placement. We advise using this CMFM
method for aneurysms anatomically unsuitable for EVAR, TEVAR, or FEVAR and for patients unﬁt for open repair.Objectives: Our aim was to assess the feasibility and efﬁcacy of the Cardiatis multilayer ﬂow modulator in the
treatment of complex aorta aneurysms.
Methods: This is a single-center prospective registry. Six patients (4 males and 2 females; mean age 74 years)
with complex aorta aneurysms (unsuitable for endovascular repair with standard, fenestrated, or branched stent
grafts) were treated with the Cardiatis multilayer ﬂow modulator.
Results: Clinical success was 100%. Median follow-up was 10 months. One patient died the third postoperative
day due to aneurysm rupture. Four aneurysms were completely thrombosed between 1 and 6 months after the
procedure. The patency of the covered aortic branches was 100%. At 6 months, the sac volume was decreased in
two patients, increased in two patients and remains stable in one patient. There were no stent migrations,
retractions, thrombosis, fractures, or reinterventions.
Conclusions: The device preserves ﬂow into the covered aortic branches and completed aneurysm thrombosis
occurs gradually; however, the stent did not prevent rupture immediately after the implantation. Longer follow-
up is mandatory to prove the efﬁcacy of this technology.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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The main goal when treating thoracic, abdominal and
thoracoabdominal aortic aneurysms (TAA, AAA, TAAA) is to
prevent rupture and death. Open surgical repair and
replacement of the aneurysmal aortic segment with a
synthetic graft has been the ﬁrst choice of therapy for over
40 years. In the last decade, endovascular repair has
increasingly become more popular and consists of placing a
stent graft into the aneurysmal sac with proximal and distal
ﬁxation at the healthy arterial segments. Several random-
ized trials have shown that endovascular aortic repair
(EVAR) and thoracic endovascular aortic repair (TEVAR) in
patients with favorable aorta anatomy is safe and feasble.1eresponding author. E. Debing, Department of Vascular Surgery,
itair Ziekenhuis Brussel, Free University of Brussels, Laarbeeklaan
1090 Brussels, Belgium.
il address: erik.debing@uzbrussel.be (E. Debing).
-5884/$ e see front matter  2014 European Society for Vascular
. Published by Elsevier Ltd. All rights reserved.
//dx.doi.org/10.1016/j.ejvs.2014.02.0204 Complex aneurysms that involve important side branches
are unsuitable for “classical” EVAR or TEVAR techniques, but
may be excluded with fenestrated (FEVAR) or branched
stent grafts.5 These techniques are technically demanding
and complex and the devices are costly and need to be
individually customized, which results in a delay of manu-
facture and planning. It limits their applicability, especially
in an emergency procedure. The chimney EVAR (Ch-EVAR)
can be a valid alternative in the urgent setting in patients
unﬁt for open complex aneurysm repair.6 These chimney
and snorkel graft techniques may also be considered in
patients that are anatomically unsuitable for FEVAR or
branched EVAR; however, long-term results of comparison
series are not available.
Recently, a new type of uncovered multilayer stent
technology has been developed (Cardiatis, Isne, Belgium).
During recent years, multiple articles have been published
concerning the successful application of the Cardiatis
multilayer ﬂow modulator (CMFM) in peripheral, visceral,
complex TAAA and juxtarenal aneurysms.7 However, the
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limited.
We report our clinical experience and the results of the
follow-up of six patients with complex aneurysms (unsuit-
able for open repair and without opportunity to use
fenestrated or branched grafts) treated with the CMFM.
MATERIAL AND METHODS
Between March 2012 and December 2012 six patients (4
males and 2 females; mean age 74 years, range 64e80
years) underwent aneurysm repair with the CMFM. Written
informed consent was obtained from all the subjects.
Technical success is deﬁned as successful introduction and
deployment of the CMFM in the absence of surgical con-
version or mortality from the initiation of the procedure
and throughout the ﬁrst 24 hours resulting in a patent
CMFM without signiﬁcant twist, kinks, or obstruction.
The indications were a recurrent 65-mm aortic arch
aneurysm (after the Bentall procedure) involving all the
supra-aortic branches; a 67-mm type III TAAA (after previ-
ous open infrarenal AAA repair) involving the renal arteries,
the superior mesenteric artery, and the celiac trunk; a 60-
mm juxtarenal AAA with a severely angulated neck of 95
degrees; a 59-mm juxtarenal saccular AAA; a recurrent fast-
growing 58-mm juxtarenal AAA after previous open repair
for ruptured infrarenal AAA; and a 72-mm juxtarenal AAA
with severe calciﬁcation at the level of the landing zones.
All these patients were anatomically unsuitable for EVAR,
TEVAR, or FEVAR and were unﬁt for open repair. One pa-
tient suffered from chronic renal insufﬁciency with a
glomerular ﬁltration rate of 24 mL/min.
Preoperative diagnostic work-up consisted of total aorta
contrast-enhanced computed tomography (CT) scans
reconstructed from 1-mm axial slices. The diameters and
the lengths of the aneurysms and the landing zones were
measured and all the aortic branches were evaluated forTable 1. Type of aneurysm and the number of the stents, oversizing a
Number of stents used
65-mm aortic arch aneurysm 3 in aortic arch
67-mm type III thoracoabdominal
aortic aneurysm
2 in thoracic abdominal aort
60-mm juxtarenal AAA 2 abdominal aorta
59-mm juxtarenal saccular AAA 2 in abdominal aorta
2 in iliac arteries
Recurrent fast growing 58-mm
juxtarenal aneurysm
2 in abdominal aorta
1 in iliac arteries
72-mm juxtarenal AAA 2 in abdominal aorta
Note. AAA ¼ abdominal aortic aneurysm.severe stenosis. Stenosis of more than 30% of the vital
branch arteries must be treated before the CMFM proce-
dure. In our series we noted no stenosis.
The CMFM interventions were performed under endo-
tracheal general anesthesia with invasive blood pressure
monitoring. The femoral accesses were percutaneous with a
closure device in two patients and surgical in the other four.
In all the cases, the CMFMs were introduced under systemic
heparinization through a 20F introducer inserted into the
right femoral artery; control angiograms were done using a
5F graduated pigtail catheter via the left femoral artery.
Regardless of the aneurysm’s diameter, the stent size was
chosen between 15% and 25% of the native aortic diameter.
When multiple stents are required, a minimal 5-cm overlap
of the stents was attempted. Table 1 describes the number
of CMFMs deployed per patient, the degree of oversizing,
and the covered overstented branch arteries.
Postoperative follow-up with CT angiography was sched-
uled at 1, 6, and 12 months. The maximum sac diameter was
measured in stretch views and the volumes of the aneurysms,
including the thrombus, on the preoperative and post-
implantation CTscans were calculated by an independent and
blinded operator (Department of Radiology) using a dedi-
cated vascular analysis software package Semi-Automatic
Thrombus Extraction (Vessel IQ Xpress, GE Healthcare, Mil-
waukee, WI, USA). With this program, the boundaries of the
aneurysmswere semi-automatically extracted and, if needed,
manually edited on every axial slice with extrapolation to the
neighboring slices to automatically adapt the corrected con-
tours along the length of the stent.
RESULTS
Technical success was obtained in all cases. Table 2 shows
the procedure and ﬂuoroscopy time, blood loss and
contrast volume. The ﬁnal completion angiograms showed
normal patency of the aorta and the CMFMS, and all thend the branch arteries.
Oversizing Covered overstented branch arteries
Proximal: 20%
Distal: 15%
Brachiocephalic trunk
Left carotid artery
Left subclavian artery
a Proximal: 20%
Distal: 20%
Celiac trunk
Superior mesenteric artery
Right and left renal artery
Proximal: 20%
Distal: 15%
Celiac trunk
Superior mesenteric artery
Right and left renal artery
Proximal: 25%
Distal: 15%
Celiac trunk
Superior mesenteric artery
Right and left renal arteries
Left and right internal iliac arteries
Proximal: 20%
Distal: 15%
Celiac trunk
Superior mesenteric artery
Right and left renal arteries
Left internal iliac arteries
Proximal: 25%
Distal: 20%
Superior mesenteric artery
Right and left renal arteries
Table 2. Operative details.
Procedure time (min) Fluoroscopy time (min) Blood loss (mL) Contrast volume (mL)
Case 1 50 23 <100 55
Case 2 55 28 <100 70
Case 3 45 23 <100 40
Case 4 40 35 <100 55
Case 5 40 27 <100 45
Case 6 55 31 150 55
606 E. Debing et al.overstented branch arteries remained patent. No ischemic
events were recorded. The renal function remained stable in
all patients. However, one patient died on the third post-
operative day from hemorrhagic shock due to aneurysm
rupture (Fig. 1). All other patients recovered uneventfully
and were discharged from hospital within 3 days of the
procedure.
The median follow up was 10 months (range 6e15
months).
CT angiographies at 1 month showed complete aneurysm
thrombosis in two patients; thrombosis of two other an-
eurysms was seen at the CT images at 6 months. In one
patient, a CT scan at 6 months showed incomplete throm-
bosis of the aneurysmal sac: minimal contrast extravasation
through the stent was seen at the level of the celiac trunk
(Fig. 2).
Table 3 shows the CMFM ﬂow modulation effects on the
volume of the aortic sac of each case, measured at baseline,
and the 6-month postoperative CT angiographies. At 6
months, the sac volume was decreased in two patients,
increased in two patients, and remains stable in one
patient.
The patency of the 25 covered aortic branches was 100%
(Fig. 3). There were no ruptures, stent migrations, re-
tractions, thrombosis, fractures, or reinterventions.DISCUSSION
CMFM: concept and design
The CMFM is a bare, self-expanding, braided wire tube of
metallic cobalt alloy wire constructed in multiple inter-
connecting layers with spatial three-dimensionalFigure 1. Ruptured abdominal aortic aneurysm 3 days after Car-
diatis multilayer ﬂow modulator implantation.geometrical structures. The purpose of the three-
dimensional multilayer technology platforms is that it
modulates hemodynamic ﬂow within the affected arterial
segment. The multilayer stent design, by virtue of its three-
dimensional geometry, reduces ﬂow velocity within the
aneurysm vortex while improving laminar ﬂow in the main
artery and surrounding vital branches.8 The CMFM is an off-
the-shelf device that does not need to be customized to a
patient’s speciﬁc aortic anatomy. Signiﬁcantly more than
30% stenosis of the side branches must be treated before
the CMFM implantation. The distal and proximal parts of the
CMFM have to be oversized between 15% and 25%
compared with the native aortic diameter. CMFM stent di-
ameters and lengths of respectively 20e45 mm and 80e
200 mm are available for implantation in the thor-
acoabdominal aorta and the stents are 18F sheath
compatible.
The behavior of the CMFM has been examined in silico,
in vitro, in vivo, and in clinical settings. Recently, Zhang
et al.7 reviewed 23 articles concerning the clinical use of the
CMFM. Successful application of the CMFM in the treat-
ment of visceral, renal, and peripheral aneurysms is
described but limited to case reports and small series. The
largest multicenter, prospective, voluntary registry was ﬁrst
reported by Rufﬁno et al.9 This registry included 35 patientsFigure 2. Computed tomography angiography showed minimal
contrast medium into the aneurysmal thrombus at the level of the
celiac trunk.
Table 3. Cardiatis multilayer ﬂow modulator effects on the volume of aortic sacs.
Total volume Case 1 Case 2 Case 3 Case 4 Case 5 Mean
Baseline (mL) 197.1 252.2 96.8 106.3 374.0 cm3 205.3
At 6 months (mL) 201.1 245 97.1 103.1 395.8 cm3 208.4
% change þ2 2.85 þ0.3 3 þ5.8 þ2.2
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aneurysms treated with a CMFM. At 1-year follow-up, the
authors noted no aneurysm rupture, a primary and sec-
ondary stent patency rate of 83.9% and 90.7%, side branch
patency of 96.1%, complete aneurysm thrombosis of 93.3%,
and aneurysm diameter reduction of 11%.
These encouraging results have prompted authors to
extend this technique to complex AAA and TAAAs. Many
successful case reports have been published, including HIV-
related AAA,10 TAAA of tuberculous origin,11 atherosclerotic
TAAA,12 and thoracoabdominal residual type B dissection.13
Recently, Sultan et al.14 reported the 1-year results of the
CMFM in the management of TAAA and Standford type B
dissection. This retrospective review of 55 patients treated
in 11 countries between August 2010 and May 2012
showed a technical success and a 30-day mortality of
respectively 98.2% and 0%. At 1 year, aneurysmal-related
survival was 93.7%, intervention-free survival was 92.4%,
and all of the 202 covered side branches were patent.
To our knowledge, this report contains the largest single
institution experience with CMFM for complex aorta an-
eurysms. Moreover, no studies of CMFM in aortic archFigure 3. Twelve months after Cardiatis multilayer ﬂow modulator
implantation, all the overstented branch arteries are patent and
there is still ﬂow in the aneurysm.aneurysms with overstenting of all the supra-aortic
branches have ever been published.
We have learned that implantation of a CMFM into an
aneurysm is an easy and simple intervention without time-
consuming catheterization and stenting of the side
branches. It saves contrast volume, radiation exposure,
time, and additional equipment. Our outcome data conﬁrm
previous ﬁndings from the literature: all the covered over-
stented vital branch arteries remained patent during the
follow-up; four of the six patients had a completely
thrombosed aneurysm between 1 and 6 months after the
implantation. One patient had an “endoleak type 2” at the
level of the celiac trunk. Despite the thrombosis, in two of
the ﬁve patients we noted at 6 months an increase in sac
volume. This slight increase in sac volume was also detected
by Sultan et al.14 A probable explanation for the increase is
the change from turbulent uncontrolled ﬂow toward a more
physiological laminar ﬂow pattern within the aneurysm sac.
We lost one patient due to an aneurysm rupture 3 days
after CMFM implantation. Autopsy conﬁrmed the diagnosis
of aneurysm rupture at the left posterior side and correct
stent placement into the aneurysm; however, a technical
error cannot be excluded.
Our experience shows that in spite of correct stent
placement, thrombosis of the aneurysmal sac is delayed and
gradual. This means that patients are not instantly pro-
tected from rupture after stent placement; in two of our
patients it took between 1 and 6 months to achieve a
complete thrombosis. Moreover, in two of our patients, we
saw an increase in sac volume at 6 months. Longer follow-
up will clarify whether there is further growth progression
and association with rupture.
At the moment, we advise using the CMFM method for
patients with complex aneurysms anatomically unsuitable
for EVAR, TEVAR, or FEVAR, and for patients unﬁt for open
repair. Patients and families must be informed that pro-
tection from aneurysm rupture is likely to follow but is not
immediate after CMFM implantation.
Before using this method in a large human population,
further clearly deﬁned registries or randomized trials are
desirable. A large-scale French clinical study to evaluate the
outcome of the treatment of AAA and TAA is underway
(AFSSAPS, protocol 2008-A01396-49/A).
CONCLUSION
Our clinical experience has shown that implantation of a
CMFM into an aneurysm is an easy and simple intervention
with off-the-shelf availability. The device preserves the ﬂow
into the covered overstented vital branch arteries. Completed
aneurysm thrombosis occurs gradually and partially after
intervention; however, an increase in sac volume is possible.
608 E. Debing et al.Delayed thrombosis of the aneurysmal sac means that the
aneurysm is not always effectively excluded for the ﬁrst
months after stent placement. Further follow-up is manda-
tory to prove the efﬁcacy of this technology.
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